ARTICLE | Clinical News

Retrophin jumps on Phase II FSGS data

September 7, 2016 7:00 AM UTC

Retrophin Inc. (NASDAQ:RTRX) rose $4.49 (28%) to $20.81 on Wednesday after it said combined data from the three cohorts of the Phase II DUET study showed sparsentan ( RE-021) met the trial's primary endpoint to treat focal segmental glomerulosclerosis. FSGS is a rare disease with progressive scarring of the kidney that often leads to end-stage renal disease.

Patients who received 200, 400 and 800 mg oral sparsentan once daily for eight weeks had a combined 44.8% reduction of proteinuria, compared with an 18.5% reduction for patients who received oral irbesartan, an angiotensin II type 1 (AT1) receptor ( AGTR1) antagonist commonly prescribed to treat FSGS and proteinurea (p=0.006). Retrophin said the individual sparsentan doses "showed clear signals of relative improvement, but did not reach statistical significance." ...